Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Stanford Healthcare – Spinal Muscular Atrophy
213 Quarry RoadPalo Alto, California, United States
Phone Web
Stanford Neuromuscular Program has extensive experience in diagnosing and treating spinal muscular atrophy (SMA). We are at the forefront of developing and validating new treatment approaches, such as Spinraza, the only treatment available for spinal muscular atrophy.
This disease-modifying drug halts the progression of spinal muscular atrophy and may help people regain some of the motor function they have lost. Our research team treated the first infant ever to receive Spinraza in 2013. After the FDA approved Spinraza in 2016, we treated the very first adult living with spinal muscular atrophy.
We offer specialized, comprehensive care for those living with spinal muscular atrophy at our multidisciplinary Neuromuscular Clinic Program.
Related Content
-
Parent Perceptions in Choosing Treatment for Infants With Spinal Muscular Atrophy Diagnosed Through Newborn Screenin...Objective: To identify factors parents c...
-
Despite Taking Spinraza, SMA Type 1 Children Show Nonmotor ProblemsDespite its well-reported benefits in mo...
-
Looking After Your Child Who Has Had a Recent Diagnosis of SMA Type 3Your child should receive care from memb...
-
Combination Therapy With Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type ISpinal muscular atrophy (SMA) is a neuro...
-
Biogen Announces New Updates Across Its SMA Research Program at 2022 MDA ConferenceBiogen Inc. announced new data and updat...
-
Detection of Spinal Muscular Atrophy Patients Using Dried Saliva SpotsSpinal muscular atrophy (SMA) is a lower...
-
CHOP – Spinal Muscular Atrophy (SMA)Why Choose CHOP for SMA Treatment?Being ...